Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479844 | 0.93 | ACHE (0.52) | ACHESMN1; SMN2KMT2AHSD11B1CHRM4 | |
| SCHEMBL11919057 | 0.86 | SMN1; SMN2 (0.46) | ACHESMN1; SMN2KMT2AHSD11B1CHRM4 | |
| SCHEMBL11919197 | 0.83 | HSD11B1 (0.63) | ACHESMN1; SMN2KMT2AHSD11B1KDM4E | |
| SCHEMBL11919252 | 0.83 | POLB (0.53) | ACHESMN1; SMN2KMT2AHSD11B1CHRM4 | |
| SCHEMBL11919192 | 0.81 | ACHE (0.48) | ACHESMN1; SMN2KMT2AHSD11B1CHRM4 | |
| SCHEMBL2551572 | 0.81 | KDM4E (0.43) | ACHESMN1; SMN2KMT2ATDP1KDM4E | |
| SCHEMBL2553841 | 0.81 | HRH3 (0.44) | KDM4EALDH1A1ALOX15POLB | |
| SCHEMBL2748651 | 0.80 | KDM4E (0.53) | HSD11B1TDP1KDM4EALDH1A1 | |
| SCHEMBL11919058 | 0.80 | KMT2A (0.56) | ACHESMN1; SMN2KMT2ACHRM4KDM4E | |
| SCHEMBL11919045 | 0.80 | KMT2A (0.56) | ACHESMN1; SMN2KMT2AHSD11B1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101952276-B | 5-halo substituted oxindole derivatives and their use for the treatment of vasopressin dependent diseases | ABBOTT GMBH & CO.KG (DE) | 2014-10-22 | — | — | CN | claimed |
| CN-101952276-B | 5-halo substituted oxindole derivatives and their use for the treatment of vasopressin dependent diseases | ABBOTT GMBH & CO.KG (DE) | 2014-10-22 | — | — | CN | disclosed |
| CN-101952276-A | 5-halo substituted oxindole derivatives and their use for the treatment of vasopressin dependent diseases | ABBOTT GMBH & CO KG | 2011-01-19 | — | — | CN | disclosed |
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | ACHE 188/4885SMN1; SMN2 1897/4885KMT2A 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.